Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-22T18:19:35.604Z Has data issue: false hasContentIssue false

MARKOV MODELING AND DISCRETE EVENT SIMULATION IN HEALTH CARE: A SYSTEMATIC COMPARISON

Published online by Cambridge University Press:  28 April 2014

Lachlan Standfield
Affiliation:
Centre for Applied Health Economics, School of Medicine & Griffith Health Institute, Griffith University
Tracy Comans
Affiliation:
Centre for Applied Health Economics, School of Medicine & Griffith Health Institute, Griffith University
Paul Scuffham
Affiliation:
Centre for Applied Health Economics, School of Medicine & Griffith Health Institute, Griffith University

Abstract

Objectives: The aim of this study was to assess if the use of Markov modeling (MM) or discrete event simulation (DES) for cost-effectiveness analysis (CEA) may alter healthcare resource allocation decisions.

Methods: A systematic literature search and review of empirical and non-empirical studies comparing MM and DES techniques used in the CEA of healthcare technologies was conducted.

Results: Twenty-two pertinent publications were identified. Two publications compared MM and DES models empirically, one presented a conceptual DES and MM, two described a DES consensus guideline, and seventeen drew comparisons between MM and DES through the authors’ experience. The primary advantages described for DES over MM were the ability to model queuing for limited resources, capture individual patient histories, accommodate complexity and uncertainty, represent time flexibly, model competing risks, and accommodate multiple events simultaneously. The disadvantages of DES over MM were the potential for model overspecification, increased data requirements, specialized expensive software, and increased model development, validation, and computational time.

Conclusions: Where individual patient history is an important driver of future events an individual patient simulation technique like DES may be preferred over MM. Where supply shortages, subsequent queuing, and diversion of patients through other pathways in the healthcare system are likely to be drivers of cost-effectiveness, DES modeling methods may provide decision makers with more accurate information on which to base resource allocation decisions. Where these are not major features of the cost-effectiveness question, MM remains an efficient, easily validated, parsimonious, and accurate method of determining the cost-effectiveness of new healthcare interventions.

Type
Methods
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Weinstein, MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics. 2006;24:10431053.Google Scholar
2. Karnon, J, Brown, J. Selecting a decision model for economic evaluation: a case study and review. Health Care Manag Sci. 1998;1:133140.Google Scholar
3. Kouemou, G. History and theoretical basics of hidden Markov Models. In: Dymarski, P, ed. Hidden Markov models, theory and applications. University Campus STeP Ri Slavka Krautzeka 83/A 51000 Rijeka, Croatia: InTech; 2011.Google Scholar
4. Drummond, M, Sculpher, M, Torrance, G, O'Brien, B, Stoddart, G. Economic evaluation using decision analytic modelling. Methods for the economic evaluation of health care programs, 3rd ed. Oxford: Oxford University Press; 2005.Google Scholar
5. Sonnenberg, FA, Beck, JR. Markov models in medical decision making: A practical guide. Med Decis Making. 1993;13:322338.Google Scholar
6. Hollocks, B. Forty years of discrete-event simulation: A personal reflection. J Oper Res Soc. 2006;57:13831399.Google Scholar
7. Brennan, A, Chick, SE, Davies, R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15:12951310.Google Scholar
8. Barton, P, Bryan, S, Robinson, S. Modelling in the economic evaluation of health care: Selecting the appropriate approach. J Health Serv Res Policy. 2004;9:110118.Google Scholar
9. Caro, JJ, Moller, J, Getsios, D. Discrete event simulation: The preferred technique for health economic evaluations? Value Health. 2010;13:10561060.Google Scholar
10. Cooper, K, Brailsford, SC, Davies, R, Raftery, J. A review of health care models for coronary heart disease interventions. Health Care Manag Sci. 2006;9:311324.CrossRefGoogle ScholarPubMed
11. Heeg, BMS, Damen, J, Buskens, E, et al. Modelling approaches: The case of schizophrenia. Pharmacoeconomics. 2008;26:633648.Google Scholar
12. Hollingworth, W, Spackman, DE. Emerging methods in economic modeling of imaging costs and outcomes. A short report on discrete event simulation. Acad Radiol. 2007;14:406410.CrossRefGoogle Scholar
13. Hughes, D, Cowell, W, Koncz, T, Cramer, J. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health. 2007;10:498509.CrossRefGoogle ScholarPubMed
14. Kamal, KM, Miller, LA, Kavookjian, J, Madhavan, S. Alternative decision analysis modeling in the economic evaluation of tumor necrosis factor inhibitors for rheumatoid arthritis. Semin Arthritis Rheum. 2006;36:5060.Google Scholar
15. Kim, SY, Goldie, SJ. Cost-effectiveness analyses of vaccination programmes: A focused review of modelling approaches. Pharmacoeconomics. 2008;26:191215.Google Scholar
16. Caro, JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics. 2005;23:323332.Google Scholar
17. Heeg, BM, Buskens, E, Knapp, M, et al. Modelling the treated course of schizophrenia: Development of a discrete event simulation model. Pharmacoeconomics. 2005;23(Suppl 1):1733.Google Scholar
18. Karnon, J. Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: A stochastic economic evaluation. Pharmacoeconomics. 2002;20:119137.Google Scholar
19. Lindgren, P, Geborek, P, Kobelt, G. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. Int J Technol Assess Health Care. 2009;25:181189.Google Scholar
20. Xenakis, JG, Kinter, ET, Ishak, KJ, et al. A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data. Pharmacoeconomics. 2011;29:497510.CrossRefGoogle ScholarPubMed
21. Tran-Duy, A, Boonen, A, Van De Laar, MAFJ, Franke, AC, Severens, JL. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis. Ann Rheum Dis. 2011;70:21112118.Google Scholar
22. Karnon, J, Stahl, J, Brennan, A, et al. Modeling using discrete event simulation: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Med Decis Making. 2012;32:701711.Google Scholar
23. Caro, JJ, Briggs, AH, Siebert, U, Kuntz, KM, Force I-SMGRPT. Modeling good research practices–overview: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32:667677.Google Scholar
24. Le Lay, A, Despiegel, N, Francois, C, Duru, G. Can discrete event simulation be of use in modelling major depression? Cost Eff Resour Alloc. 2006;4:111.Google Scholar
25. Karnon, J. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ. 2003;12:837848.Google Scholar
26. Simpson, KN, Strassburger, A, Jones, WJ, Dietz, B, Rajagopalan, R. Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics. 2009;27:159165.Google Scholar